|Bid||82.75 x 100|
|Ask||82.87 x 800|
|Day's Range||79.85 - 83.33|
|52 Week Range||24.44 - 92.56|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.95%|
Biotechnology and pharmaceutical ETFs have rallied in recent weeks as drug pricing concerns wane and investors look to the opportunity of this market segment. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) ...
Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI ) , one of the largest biotechnology ETFs, is one of this year's best-performing non-leveraged ETFs. That does not mean XBI's run ...
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotechnology exchange traded fund by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI) have been soaring in ...
Even with modest August losses for the S&P 500 and the broader healthcare sector, biotechnology stocks and exchange traded funds (ETFs) are surging. The S&P Biotechnology Select Industry Index is up more ...
The SPDR S&P Biotech ETF (NYSEArca: XBI) , one of the largest biotechnology exchange traded funds, is getting in on the sector's resurgence. XBI, an equal-weight fund, is up about 7% over the past week, ...
U.S. ETFs are on pace to have record inflows in 2017. That includes funds dedicated to equities, fixed income, and commodities. And it's easy to see why. With the S&P 500 up 9 percent this year (through ...
The Zacks Analyst Blog Highlights: Direxion Daily S&P Biotech Bull 3X ETF, Direxion Daily South Korea Bull 3X ETF, Direxion Daily CSI China Internet Bull 2X Shares, Direxion Daily Hmbldrs&Supls Bull 3X ETF and Direxion Daily MSCI India Bull 3x ETF
The summer months can be a lethargic period for equities. While that scenario can lead some investors to flock to defensive sectors, there are some seasonal surprises that active, risk-tolerant traders ...
With names like AbbVie and Celgene on a tear the past week, many biotech sector ETFs hit 52-week or longer highs.
Rising interest rates don't negatively affect healthcare as much as some other industries. But it has still underperformed since the US elections.
Do you know how leveraged and inverse ETFs work? Find out in this edition of the Dutram Report, where we discuss that topic, and some of the hottest funds in the leveraged and inverse ETF world right now.
Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.
President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.
Donald Trump wants to repeal the Affordable Care Act (or ACA) and replace it with a new act that encourages free-market competition.
2016 has been a tough year for the biotech sector, as drug pricing became a very popular topic among politicians and media outlets, which dubbed many of the industry’s practices as “price gouging”. Controversies around Mylan NV (NASDAQ:MYL) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were among the most notable in a series of cases that galvanized […]